Elizabeth Plimack MD

How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage future research.

How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State www.nytimes.com/interactive/...

Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!

#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social

4.75 Million Lives Saved, and Counting Podcast Episode · The Good News About Cancer · 02/11/2025 · 23m

Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with

ORR of 41%
DCR 90%
50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor

@MSKCancerCenter #ASCOGU #GU25

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

Watching #BCR session @asco #GU25 it is very clear there is a drive to treat #BCR asap esp w/+ #PSMA

But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below

ascopubs.org/doi/10.1200/...

Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25

Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer

www.nature.com/articles/s41...

SUPER BOWL CHAMPIONS!
THIS ONE’S FOR YOU PHILLY!

Trump & Musk are making massive cuts to the National Institutes of Health.

I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

Both ERA Commons and NIH Reporter are currently unavailable.

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:

- Bladder Ca
- Prostate Ca
- RCC

*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25

#OncSky #MedSky #gusm #Oncology #Cancer #CanSky

The New England Journal of Medicine Perioperative Chemotherapy in Esophageal Cancer A PLAIN LANGUAGE SUMMARY Illustration of resectable esophageal adenocarcinoma. Read the full Plain Language Summary at NEJM.org.

In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5

#MedSky #Oncology

Hello, #MedSky community! We’re excited to begin our Bluesky journey.

Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)☆ In human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) b...

Great work! This link worked better for me. www.annalsofoncology.org/article/S092...

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.

FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma @fda.gov #oncology
www.onclive.com/view/fda-gra...

Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story.

Signal: thealexknapp.79
Email: aknapp@forbes.com

EMA celebrates 30 years of progress in science and medicines in the European Union | European Medicines Agency (EMA) Agency marks milestone highlighting its changing role in Europe

🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe.

Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...

EU medicines agency quits X, moves to Bluesky The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.

This is huge.

The European equivalent to the FDA has said enough to the propaganda machine X.

Others will follow.

#medsky #oncosky

www.reuters.com/world/europe...

The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them.

Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments.

Creative tension makes beautiful music.

Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app!

Please comment if you want to be added!

bsky.app/start/did:pl...

@pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social

Bluesky’s science takeover: 70% of Nature poll respondents use platform Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X.

Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X

https://go.nature.com/42tH8Ai

Thanks Esther for this explainer, I hope it reaches the right audience. The complexity of health research is not widely appreciated, yet the diseases scientists are trying to cure affect us all.

Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications - OncoDaily Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications / Amy Babler, cancer, Fox Chase Cancer Center, Jeremy Moore, OncoDaily,

Remembering Amy Babler: A fearless Advocate for Cancer Awareness and Communications
@foxchasesurgonc.bsky.social

oncodaily.com/blog/amy-bab...

#Cancer #OncoDaily #Oncology #Medicine #Health

Thrilled to announce that my dear friend and colleague, Jay Simhan, MD, FACS, has been named Chair of Urology at Temple University Hospital!

I’m thrilled to partner as two departments under the Fox Chase-Temple Urologic Institute to elevate our already world-class program to even greater heights!

This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️